Testing a new blood cancer treatment for patients who haven't responded to other drugs

Plain-English translation of NCT05131022 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new drug called for people with B-cell blood cancers (like lymphoma or leukemia) that have stopped responding to standard treatments. The medication works differently than previous drugs by targeting and breaking down a specific protein involved in cancer growth. Researchers are first figuring out the safest dose, then testing whether the medication actually shrinks tumors.

Many patients with advanced B-cell cancers run out of effective treatment options after their disease becomes resistant to standard drugs. This trial exists to develop a new treatment option for people in that difficult situation.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with a B-cell blood cancer (such as lymphoma or leukemia) that has returned or stopped responding to previous treatments
you have already tried at least 2 prior cancer treatments (or 1 treatment if you have a specific brain lymphoma)
you have measurable disease that can be tracked during the study
you are in generally good health with adequate organ and bone marrow function

You likely don't qualify if…

you have received chemotherapy, antibody therapy, or other cancer drugs within the past 2 weeks (or specific timeframes depending on the drug type)
you have had stem cell transplant or CAR T-cell therapy within the past 100 days
you are currently taking high doses of corticosteroids or other immunosuppressive medications
you have previously been treated with a BTK degrader (another type of targeted drug)
you have active, uncontrolled autoimmune hemolytic anemia

What participation looks like

In the first phase, you will visit the study clinic regularly to receive increasing doses of the medication and have blood tests and imaging scans to monitor safety and how your cancer responds. The study is divided into stages: first, researchers test different dose levels to find the safest amount; then, larger groups of patients with specific cancer types receive the selected dose while doctors continue to watch for side effects and measure tumor shrinkage. Your participation may last several months or longer depending on how well the treatment works and how you tolerate it.

AI-generated summary from trial data · Jul 11, 2026 · Not medical advice

Trial locations(62 sites)

United States

City of Hope, Duarte, California

University of California, San Francisco, San Francisco, California

Colorado Blood Cancer Institute, Denver, Colorado

Yale Cancer Center, New Haven, Connecticut

University of Miami, Miami, Florida